Page last updated: 2024-10-30

memantine and Dizzyness

memantine has been researched along with Dizzyness in 8 studies

Research Excerpts

ExcerptRelevanceReference
"Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease."5.62[Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021)
"Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist."3.80A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). ( Möbius, HJ; Stöffler, A; Wilcock, G, 2002)
"The primary objective was to assess the safety and tolerability of rivastigmine capsules 6-12 mg/day plus memantine (5-20 mg/day) as measured by the incidences of vomiting and nausea compared with those reported in the rivastigmine United States Prescribing Information (US PI)."3.76Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). ( Bhatnagar, V; Brannan, S; Koumaras, B; Meng, X; Olin, JT; Reyes, P, 2010)
" In addition, many adverse reactions were observed in these patients."2.82Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. ( Brassat, D; Brochet, B; Cabre, P; Castelnovo, G; Clavelou, P; Coman, I; Creveuil, C; Daplaud, D; De Seze, J; Debouverie, M; Defer, G; Dupuy, B; Hautecoeur, P; Heinzlef, O; Lebiez, P; Lebrun-Frenay, C; Pelletier, J; Peyro Saint Paul, L; Sartori, É; Tourbah, A; Vermersch, P, 2016)
"Memantine was well tolerated with a frequency of adverse events comparable to placebo."2.70Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). ( Forette, F; Möbius, HJ; Orgogozo, JM; Rigaud, AS; Stöffler, A, 2002)
"Memantine was found to have a favourable tolerability profile when used as monotherapy or in combination with other agents."2.46A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. ( Jones, RW, 2010)
"Dizziness is not a unique clinical picture, but rather is the unspecific symptom of numerous diseases."2.44[Frequently occurring forms of dizziness and their treatment]. ( Thömke, F, 2007)
"Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease."1.62[Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Shimoyama, T1
Aoki, Y1
Kaneda, M1
Han, LK1
Michihara, S1
Takahashi, R1
Peyro Saint Paul, L1
Creveuil, C1
Heinzlef, O1
De Seze, J1
Vermersch, P1
Castelnovo, G1
Cabre, P1
Debouverie, M1
Brochet, B1
Dupuy, B1
Lebiez, P1
Sartori, É1
Clavelou, P1
Brassat, D1
Lebrun-Frenay, C1
Daplaud, D1
Pelletier, J1
Coman, I1
Hautecoeur, P1
Tourbah, A1
Defer, G1
Olin, JT1
Bhatnagar, V1
Reyes, P1
Koumaras, B1
Meng, X1
Brannan, S1
Jones, RW1
Wilcock, G1
Möbius, HJ2
Stöffler, A2
Thömke, F1
Orgogozo, JM1
Rigaud, AS1
Forette, F1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis[NCT01074619]Phase 390 participants (Actual)Interventional2005-09-30Completed
A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia[NCT00545974]Phase 481 participants (Actual)Interventional2007-10-31Completed
A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00196703]Phase 430 participants Interventional2005-03-31Recruiting
A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00640198]Phase 428 participants (Actual)Interventional2005-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Neuropsychiatric Inventory (NPI)

NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions indicate that the patient has problems with a particular sub-domain of behavior, the caregiver is only then asked all the questions about that domain, rating the frequency of the symptoms on a 4-point scale, their severity on a 3-point scale, and the distress the symptom causes them on a 5-point scale. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement. (NCT00545974)
Timeframe: Baseline, 26 weeks

Interventionunits on a scale (Mean)
Memantine-1.9
Placebo0.3

Clinical Global Impression of Change (CGIC)

The scale is rated on a 7-point scale, using a range of responses from 1 (very much improved) through 7 (very much worse). The clinician compares the participant's current condition to the condition at admission to the project. (NCT00545974)
Timeframe: 26 Weeks

Interventionunits on a scale (Mean)
Memantine4.4
Placebo4.8

Number of Participants Starting Antipsychotic Therapy

(NCT00545974)
Timeframe: 26 weeks

InterventionParticipants (Count of Participants)
Memantine1
Placebo2

Longitudinal Changes From Baseline to 26 Weeks for Test Battery: CDR-SB, FAQ, TFLS, MMSE, EXIT25, UPDRS, Boston Naming Test

"Clinical dementia rating sum of boxes CDR-SB (0-18) high scores indicate high impairment.~Functional activities questionnaire FAQ (0-30) high scores indicate high impairment.~Texas functional living scale TFLS (0 to 52) high scores suggest better instrumental activities of daily living functioning.~Mini-Mental State Examination MMSE (0-30) low scores indicate low cognition. The executive interview EXIT25 (0 to 50) high scores indicate more executive impairment.~A modified unified Parkinson's disease rating scale UPDRS (0-199) high scores indicate worse disability.~Boston naming test (0-15) low scores indicate more retrieval difficulties." (NCT00545974)
Timeframe: Baseline and 26 Weeks

,
Interventionunits on a scale (Mean)
CDR-SBFAQTFLSMMSEEXIT25UPDRSBoston naming test
Memantine1.54.3-3.7-1.21.91.7-1.4
Placebo1.52.9-2.8-0.90.71.40.7

Longitudinal Changes From Baseline to 26 Weeks for Test Battery: Letter Fluency, Category Fluency, Digit Symbol, Digits Backwards

"Letter fluency, score is number of words recalled starting with a specified letter for 60 seconds. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials for the score. Low scores indicate high impairment~Category fluency, score is number of items generated belonging to a specific category (such as animals) in 60 seconds, low scores indicate high impairment.~Digit symbol, score is number of symbols that correctly corresponded to the random numerals entered in the form in 90 seconds. Participants are given a table of numerals with matching symbols, and a form with random numerals with open spaces. Low scores indicate high impairment.~Digits backwards, score is number of digits backwards recalled (range: 0-14), The participant hears a list of digits and is asked to repeat the digits backwards. Low scores indicate high impairment." (NCT00545974)
Timeframe: Baseline and 26 Weeks

,
Interventionnumber of items recalled (Mean)
Letter fluencyCategory fluencyDigit symbolDigits backwards
Memantine-0.1-0.5-3.90.1
Placebo-0.3-0.74.2-0.2

Reviews

3 reviews available for memantine and Dizzyness

ArticleYear
A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors.
    International journal of geriatric psychiatry, 2010, Volume: 25, Issue:6

    Topics: Aged; Akathisia, Drug-Induced; Alzheimer Disease; Cholinesterase Inhibitors; Dizziness; Drug Interac

2010
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
    International clinical psychopharmacology, 2002, Volume: 17, Issue:6

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Dementia, Vascular; Dizziness; Double-Blin

2002
[Frequently occurring forms of dizziness and their treatment].
    MMW Fortschritte der Medizin, 2007, May-21, Volume: 149 Suppl 2

    Topics: Amines; Anticonvulsants; Betahistine; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnosis, Differe

2007

Trials

3 trials available for memantine and Dizzyness

ArticleYear
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    Journal of the neurological sciences, 2016, Apr-15, Volume: 363

    Topics: Adult; Cognition Disorders; Dizziness; Double-Blind Method; Excitatory Amino Acid Antagonists; Femal

2016
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
    International clinical psychopharmacology, 2002, Volume: 17, Issue:6

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Dementia, Vascular; Dizziness; Double-Blin

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
    Stroke, 2002, Volume: 33, Issue:7

    Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M

2002

Other Studies

3 other studies available for memantine and Dizzyness

ArticleYear
[Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2021, Volume: 141, Issue:7

    Topics: Administration, Oral; Alzheimer Disease; Animals; Disease Models, Animal; Dizziness; Drug Therapy, C

2021
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
    International journal of geriatric psychiatry, 2010, Volume: 25, Issue:4

    Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipa

2010
Memantine for Alzheimer's disease.
    The Medical letter on drugs and therapeutics, 2003, Sep-15, Volume: 45, Issue:1165

    Topics: Alzheimer Disease; Dizziness; Dopamine Agents; Drugs, Investigational; Humans; Memantine; Randomized

2003